AbbVieRegister for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
AbbVieImmunology-led pharma built around Skyrizi and Rinvoq after the Humira patent cliff. Entered obesity in March 2025 by licensing Gubra's long-acting amylin analog GUB014295 (GUBamy) for $350M upfront and up to $1.875B in milestones, taking global development and commercialisation.
Browse all official SEC filings including annual reports, quarterly updates, and material event disclosures.
SEC filings for this company are not available at the moment.